Medtronic plc MDT
Regular-session close
After hours · Nov 20, 6:08 PM ET
- YTD
- +4.04%
- 1 year
- +0.59%
5D -4.40 (-4.21%)
- Market cap
- 127.84B
- Revenue (ttm)
- 37.54B
- Profit margin
- 13.93%
- EPS (ttm)
- 4.07
- Shares out
- 1.28B
- P/E ratio
- 24.56
- Forward P/E
- 15.61
- Dividend
- 2.88 (2.86%)
- Ex-dividend date
- Sep 25, 2026
- YTD return
- +4.04%
- 1-year return
- +0.59%
- Volume
- 9.03M
- Avg volume
- 16.53M
- Open
- 101.42
- Previous close
- 100.61
- Day's range
- 99.60 – 102.61
- 52-week range
- 73.75 – 105.35
- Beta
- 0.57
- Analysts
- Buy
- Price target
- 106.96 (+7.0%)
- Earnings date
- Nov 24, 2026
- 50-day average
- 94.45
Key statistics
- 200-day average
- 88.24
- Enterprise value
- 148.65B
- PEG ratio
- 1.81
- Price / sales
- 3.41
- Price / book
- 2.55
- Payout ratio
- 70.02%
- Revenue growth
- 13.70%
- Free cash flow
- 5.40B
- Total cash
- 8.82B
- Total debt
- 28.15B
- Return on equity
- 10.65%
- Short % of float
- 1.80%
Fundamental scorecard
19 of 25 checks passed on MDT’s reported financials
19of 25 checks passed
- Value 2 of 5
- Growth 4 of 5
- Profitability 4 of 5
- Financial health 4 of 5
- Dividend 5 of 5
Statements to Jul 31, 2026.
Analyst view
Consensus: buy
- Target (low)
- 92.00
- Target (mean)
- 106.96
- Target (high)
- 121.00
- Strong buy3
- Buy17
- Hold10
- Sell0
- Strong sell0
Next earnings
Nov 24, 2026
Expected Nov 24, 2026. Consensus EPS estimate 1.33.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 24, 2026 | Oct 31, 2026 | 1.33 | — | — | — |
| Sep 1, 2026 | Jul 31, 2026 | 1.39 | 1.45 | +0.06 | +4.32% |
| Jun 3, 2026 | Apr 24, 2026 | 1.54 | 1.55 | +0.01 | +0.65% |
| Feb 17, 2026 | Jan 23, 2026 | 1.34 | 1.36 | +0.02 | +1.49% |
| Nov 18, 2025 | Oct 24, 2025 | 1.31 | 1.36 | +0.05 | +3.82% |
| Aug 19, 2025 | Jul 25, 2025 | 1.23 | 1.26 | +0.03 | +2.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | BTIG | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Equal-Weight |
| Sep 30, 2026 | TD Cowen | reit | Buy | Buy |
| Sep 3, 2026 | UBS | main | Buy | Buy |
| Sep 2, 2026 | Truist Securities | reit | Hold | Hold |
| Sep 2, 2026 | Wells Fargo | main | Overweight | Overweight |
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Ireland
- Website
- medtronic.com
News
Medtronic Is About to Report Its First Earnings Since Spinning Off MiniMed. Should You Buy the Stock Before Nov. 24?
18,505 Shares in Medtronic PLC $MDT Bought by Banco Santander S.A.
Medtronic (NYSE:MDT) versus Lifeward (NASDAQ:LFWD) Head-To-Head Analysis
Ahead of Medtronic (MDT) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Aecom To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday BTIG Maintains Buy on Medtronic, Raises Price Target to $109
Medtronic (MDT) Declines More Than Market: Some Information for Investors
4 High-Yield Healthcare Stocks Retirees Should Buy for December Income
Should You Continue to Hold Medtronic Stock in Your Portfolio?
4 Dividend Stocks That Can Thrive Under a Democratic Congress
Your note
Sign in to keep a note on MDT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARNOLD CRAIG | Director | Stock Award(Grant) | Apr 26, 2026 | 42,185 |
| CORONA GARY LOUIS | Chief Financial Officer | Stock Award(Grant) | Jan 20, 2025 | 44,255 |
| HOGAN RANDALL J III | Director | Stock Award(Grant) | Apr 26, 2026 | 48,998 |
| KIIL HARRY SKIP | Officer | Sale | Sep 15, 2026 | 42,186 |
| MARINARO MICHAEL | President | Stock Award(Grant) | Nov 1, 2026 | 113,353 |
| MARTHA GEOFFREY S | Chief Executive Officer | Stock Award(Grant) | Aug 2, 2026 | 327,866 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.29% | 118,770,885 | 11.88B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.55% | 83,752,662 | 8.38B | Sep 29, 2026 |
| State Street Corporation | 5.16% | 65,987,354 | 6.60B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 2.68% | 34,302,943 | 3.43B | Sep 29, 2026 |
| Geode Capital Management, LLC | 2.41% | 30,879,777 | 3.09B | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 1.70% | 21,712,856 | 2.17B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 40,757,422 | 4.08B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.60% | 33,271,457 | 3.33B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 17,056,298 | 1.71B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 16,635,418 | 1.66B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 15,820,582 | 1.58B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 0.96% | 12,221,643 | 1.22B | Jun 29, 2026 |
